Literature DB >> 31238347

Chorioamnionitis and Infectious Complications after Vaginal Delivery.

Anna E DeNoble1, R Phillips Heine2, Sarah K Dotters-Katz1.   

Abstract

OBJECTIVE: To estimate the incidence of and define risk factors for postpartum infectious complications after vaginal birth after cesarean (VBAC) complicated by chorioamnionitis. STUDY
DESIGN: A secondary analysis of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Unit Cesarean Registry was performed. The primary outcome was a composite of postpartum infection: endometritis, sepsis, pelvic abscess, urinary tract infection, necrotizing fasciitis, and septic pelvic thrombophlebitis. Peripartum predictors were compared using parametric and nonparametric tests, as appropriate, and multivariate predictors assessed using logistic regression.
RESULTS: A total of 559 subjects had chorioamnionitis in labor and a successful VBAC. Twenty-four (4.3%) subjects experienced the primary outcome, mainly due to endometritis (19/24). Significant factors included preterm delivery <32 weeks (odds ratio [OR]: 3.05, 95% confidence interval [CI]: 1.32-7.06) and body mass index (BMI) ≥40 (OR: 4.63, 95% CI: 1.25-17.14). Receipt of postpartum antibiotics was protective against postpartum infection (OR: 0.28, 95% CI: 0.12-0.65). In multivariate analysis, preterm delivery <32 weeks, BMI ≥40, and receipt of postpartum antibiotics remained associated with postpartum infection.
CONCLUSION: Nearly 5% of women with chorioamnionitis had a postpartum infectious complication after vaginal delivery, with higher rates in those delivering at <32 weeks and with prepregnancy BMI ≥40. Receipt of postpartum antibiotics decreased the odds of postpartum infection markedly. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Year:  2019        PMID: 31238347     DOI: 10.1055/s-0039-1692718

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  6 in total

1.  Postpartum septic pelvic thrombophlebitis and ovarian vein thrombosis after caesarean section: a rare case report.

Authors:  Qin Shi; Deborah Shulamite Gandi; Yurong Hua; Yi Zhu; Jinhan Yao; Xiaoqing Yang; Yunzhao Xu; Yuquan Zhang
Journal:  BMC Pregnancy Childbirth       Date:  2021-08-17       Impact factor: 3.007

2.  Internal fetal and uterine monitoring in obese patients and maternal obstetrical outcomes.

Authors:  Antonina I Frolova; Molly J Stout; Ebony B Carter; George A Macones; Alison G Cahill; Nandini Raghuraman
Journal:  Am J Obstet Gynecol MFM       Date:  2020-11-27

3.  Clinical chorioamnionitis at term X: microbiology, clinical signs, placental pathology, and neonatal bacteremia - implications for clinical care.

Authors:  Roberto Romero; Percy Pacora; Juan Pedro Kusanovic; Eunjung Jung; Bogdan Panaitescu; Eli Maymon; Offer Erez; Susan Berman; David R Bryant; Nardhy Gomez-Lopez; Kevin R Theis; Gaurav Bhatti; Chong Jai Kim; Bo Hyun Yoon; Sonia S Hassan; Chaur-Dong Hsu; Lami Yeo; Ramiro Diaz-Primera; Julio Marin-Concha; Kia Lannaman; Ali Alhousseini; Hunter Gomez-Roberts; Aneesha Varrey; Angel Garcia-Sanchez; Maria Teresa Gervasi
Journal:  J Perinat Med       Date:  2021-01-26       Impact factor: 2.716

4.  Risk Factors for Postpartum Maternal Infection Following Spontaneous Vaginal Delivery Complicated by Chorioamnionitis.

Authors:  Helen A Daifotis; Megan M Smith; Anna E Denoble; Sarah K Dotters-Katz
Journal:  AJP Rep       Date:  2020-05-15

5.  Necrotizing Fasciitis: Association with Pregnancy-related Risk Factors Early in Life.

Authors:  Gabrielle Kang-Auger; Michaël Chassé; Caroline Quach; Aimina Ayoub; Nathalie Auger
Journal:  Yale J Biol Med       Date:  2021-12-29

6.  Mixed Vaginitis in the Third Trimester of Pregnancy Is Associated With Adverse Pregnancy Outcomes: A Cross-Sectional Study.

Authors:  Huanrong Li; Mengting Dong; Wenjuan Xie; Wenhui Qi; Fei Teng; Huiyang Li; Ye Yan; Chen Wang; Cha Han; Fengxia Xue
Journal:  Front Cell Infect Microbiol       Date:  2022-03-28       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.